Study of YL201 for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new drug, YL201, in people with nasopharyngeal cancer that has come back or spread. It may be an option if you have already tried a PD-(L)1 inhibitor and at least two chemotherapy treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and can care for yourself (ECOG 0 or 1).
- Your nasopharyngeal cancer has come back or spread and cannot be cured with standard treatments.
- You have tried a PD-(L)1 inhibitor and at least two chemotherapy regimens.
- You are willing to provide a tumor sample for testing a marker called B7-H3.
- You have not had a prior treatment targeting B7-H3 or a drug called a topoisomerase I inhibitor.
- You have not had certain other cancers in the last 5 years, except for some minor ones.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (YL201 and Ivonescimab) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a new drug, JS207, which targets two proteins (PD-1 and VEGF) that help cancer grow. It's for people with nasopharyngeal cancer that has not spread too much, and who have not had certain prior treatments.
This trial tests a new combination of two drugs (YL201 and serplulimab) for people with extensive-stage small cell lung cancer who have not yet received treatment. The goal is to see if the combination helps shrink or control the cancer.
This trial tests a new drug combination for people with advanced or recurrent nasopharyngeal cancer. It aims to see if YL201 plus Toripalimab (and sometimes cisplatin) can help when standard treatments are not an option.
This trial tests a new drug called YL202 for people with advanced solid tumors (cancers that have spread or cannot be removed). It aims to see if the drug can shrink tumors or slow cancer growth. You may be able to join if you have certain types of cancer, have not had a previous HER3 treatment, and can provide a tumor sample.
This trial tests a new drug called YL202 for people with advanced breast cancer. It is for those who have already tried certain targeted treatments (HER2 or TROP2 antibody-drug conjugates) and they stopped working. The goal is to see if YL202 can help shrink tumors or slow cancer growth.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.